...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gastroenterology and hepatology >Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections
【24h】

Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections

机译：慢性乙型肝炎病毒感染长期治疗过程中拉米夫定抗性发展的危险因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/aim The use of lamivudine for the treatment of chronic hepatitis B (CHB) is limited by high rates of lamivudine resistance. However, it is still in use in many regions. Factors associated with lamivudine resistance development have been studied in only a few European cohorts. The aim of our study was to assess the rate and risk factors for lamivudine resistance in a large real-life European cohort. Patients and methods We retrospectively analyzed patients with CHB treated in three German University centers over up to 12 years. Lamivudine resistance was defined as virologic breakthrough and presence of genotypic lamivudine resistance. The probability of resistance was estimated by Kaplan-Meier analysis and resistance predictors by Cox regression. Results A total of 227 patients were included into the analysis (hepatitis B envelope antigen positive or negative). Rates of lamivudine resistance by years 1-7 were 7, 26, 35, 41, 46, 53, and 55%, respectively. Interestingly, two hepatitis B envelope antigen-negative patients developed resistance during the year 12 of treatment. Independent risk factors for resistance development were hepatitis B virus DNA levels of at least 10(7) copies/ml before and detectable hepatitis B virus DNA by month 6 of treatment. Conclusion Even after long-term response to lamivudine more than 10 years, resistance may still develop. Our findings further discourage the use of lamivudine for the treatment of CHB.
机译：背景/目的利用拉米夫定用于治疗慢性乙型肝炎（CHB）的抗性抗性率的高速率。但是，它仍在许多地区使用。只有几个欧洲队列研究了与拉米夫定抗性发展相关的因素。我们的研究目的是评估大型真实欧洲队列中拉米夫定抵抗的速率和风险因素。患者和方法我们回顾性分析了三个德国大学中心治疗的CHB患者，超过12年。拉米夫定抗性定义为病毒学突破和基因型跛行抗性的存在。通过COX回归估算阻力的概率通过考克斯分析和阻力预测因子。结果共有227名患者纳入分析（乙型肝炎包膜抗原阳性或阴性）。拉米夫定抗性的率分别为1-7的抵抗力分别为7,26,35,41,46,53和55％。有趣的是，两种乙型肝炎包膜抗原阴性患者在治疗中产生的抗性。抗性开发的独立风险因素是乙型肝炎病毒DNA水平至少10（7）份/ mL之前和可检测的乙型肝炎病毒DNA治疗。结论即使在长期反应拉米夫定十多年后，抵抗可能仍然可以发展。我们的研究结果进一步阻止了利用拉米夫定用于治疗CHB的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号